يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Tsuchihara K."', وقت الاستعلام: 0.81s تنقيح النتائج
  1. 1
    دورية أكاديمية
    KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab.

    المؤلفون: Bando, H., Yoshino, T., Tsuchihara, K., Ogasawara, N., Fuse, N., Kojima, T., Tahara, M., Kojima, M., Kaneko, K., Doi, T., Ochiai, A., Esumi, H., Ohtsu, A

    المصدر: British Journal of Cancer; 7/26/2011, Vol. 105 Issue 3, p403-406, 4p, 4 Charts, 1 Graph

    مصطلحات موضوعية: CLINICAL trials, COLON cancer treatment, CETUXIMAB, GENETIC mutation, HEALTH outcome assessment, ADENOCARCINOMA, GENETICS

    النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    90MO Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC) by microsatellite stable (MSS), RAS/BRAF, and HER2 amplification (HER2amp) status: Phase III PARADIGM biomarker study.

    المؤلفون: Kato, T.1 (AUTHOR), Muro, K.2 (AUTHOR), Watanabe, J.3 (AUTHOR), Shitara, K.4 (AUTHOR), Yamazaki, K.5 (AUTHOR), Ohori, H.6 (AUTHOR), Shiozawa, M.7 (AUTHOR), Yasui, H.5 (AUTHOR), Oki, E.8 (AUTHOR), Sato, T.9 (AUTHOR), Naitoh, T.10 (AUTHOR), Komatsu, Y.11 (AUTHOR), Soeda, J.12 (AUTHOR), Yamamoto, K.13 (AUTHOR), Yamashita, R.14 (AUTHOR), Akagi, K.15 (AUTHOR), Ochiai, A.16 (AUTHOR), Uetake, H.17 (AUTHOR), Tsuchihara, K.14 (AUTHOR), Yoshino, T.4 (AUTHOR)

    المصدر: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1503-S1504. 2p.

    مصطلحات موضوعية: *PANITUMUMAB, *COLORECTAL cancer, *BEVACIZUMAB, *METASTASIS, *MICROSATELLITE repeats


    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    P-034 - PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.

    المؤلفون: Muro, K.1 (AUTHOR), Uetake, H.2 (AUTHOR), Tsuchihara, K.3 (AUTHOR), Shitara, K.4 (AUTHOR), Yamazaki, K.5 (AUTHOR), Ota, M.6 (AUTHOR), Oki, E.7 (AUTHOR), Sato, T.8 (AUTHOR), Naitoh, T.9 (AUTHOR), Komatsu, Y.10 (AUTHOR), Kato, T.11 (AUTHOR), Yamanaka, K.12 (AUTHOR), Mori, I.13 (AUTHOR), Soeda, J.13 (AUTHOR), Hihara, M.13 (AUTHOR), Yamanaka, T.14 (AUTHOR), Akagi, K.15 (AUTHOR), Ochiai, A.16 (AUTHOR), Yoshino, T.17 (AUTHOR)

    المصدر: Annals of Oncology. 2019 Supplement, Vol. 30, piv10-iv10. 1p.

    مصطلحات موضوعية: *COLORECTAL cancer, *METASTASIS, *BEVACIZUMAB, *THERAPEUTICS

    النص الكامل

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    388P Early tumor shrinkage (ETS) and depth of response (DpR) analyses in metastatic colorectal cancer (mCRC) treated with first-line mFOLFOX6 plus panitumumab (PAN) or bevacizumab (BEV): Results from the phase III PARADIGM trial.

    المؤلفون: Muro, K.1 (AUTHOR), Watanabe, J.2 (AUTHOR), Shitara, K.3 (AUTHOR), Yamazaki, K.4 (AUTHOR), Ohori, H.5 (AUTHOR), Shiozawa, M.6 (AUTHOR), Yasui, H.4 (AUTHOR), Oki, E.7 (AUTHOR), Sato, T.8 (AUTHOR), Naitoh, T.9 (AUTHOR), Komatsu, Y.10 (AUTHOR), Kato, T.11 (AUTHOR), Hihara, M.12 (AUTHOR), Soeda, J.13 (AUTHOR), Yamamoto, K.14 (AUTHOR), Akagi, K.15 (AUTHOR), Ochiai, A.16 (AUTHOR), Uetake, H.17 (AUTHOR), Tsuchihara, K.18 (AUTHOR), Yoshino, T.19 (AUTHOR)

    المصدر: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS714-S714. 1p.

    مصطلحات موضوعية: *CLINICAL trials, *PANITUMUMAB, *COLORECTAL cancer, *BEVACIZUMAB, *METASTASIS

    النص الكامل

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث